Introduction
Malignancy-associated hypercalcemia is a common paraneoplastic syndrome occurring in up to 20% of cancer patients. The development of hypercalcemia in a cancer patient often translates to a poor prognosis [1] . Despite strategies to lower serum calcium and treat the hypercalcemic symptoms, median survival after discovery of hypercalcemia is approximately 30 days [2] . The poor prognosis is not necessarily due to the hypercalcemia itself but reflects correlation of this condition with an advanced cancer stage. Although hypercalcemia can occur with many types of malignancy, it is most often associated with breast cancer, lung cancer and multiple myeloma [3, 4] .
Signs and symptoms
Symptoms of hypercalcemia vary in individual patients and are related to both the absolute concentration and the rate of rise of serum calcium [1, 5] . Hypercalcemia associated with malignancy is likely to be more severe and rapid in onset, and therefore such patients are more likely to present with symptoms associated with acute onset. Gastrointestinal complaints that include nausea, vomiting, anorexia, abdominal pain and constipation are common. Pancreatitis is a less common but serious complication [6] . Neurologic manifestations range from fatigue to coma especially with very high calcium excursion. Psychiatric conditions such as depression, anxiety and cognitive dysfunction can occur. Shortening of the electrocardiogram QT interval and cardiac arrhythmia are associated with acute and markedly elevated serum calcium [7, 8] . Muscular weakness is a common complaint with hypercalcemia. Nephrogenic diabetes insipidus is an incompletely understood complication of hypercalcemia and is likely to be related to downregulation of aquaporin-2 water channels in the collecting ducts resulting in a renal concentrating defect [9, 10] . As a result, dehydration and intravascular volume contraction is further exacerbated by anorexia, nausea and vomiting leading to worsening hypercalcemia.
Before the discovery of parathyroid hormone-related protein (PTHrP), the presence of a parathyroid hormone (PTH)-like factor was proposed that possessed similar hypercalcemic and phosphaturic actions of PTH. In 1987, PTHrP was purified from human cancer cells [11, 12] by independent groups and cloned shortly thereafter [13] . PTHrP was subsequently found to have important biological roles in mammary gland development [14] , lactation [15] , endochondral bone formation [16] and islet beta-cell function [17] .
The PTHrP gene encodes a 141 amino acid protein that shares a 60% sequence homology with PTH over the first 13 amino acids at the N terminus [13] . Beyond the initial amino-terminal sequence, the two proteins are unique and show no further sequence homology. Other PTHrP endoproteolytic fragment species have been identified, with the PTHrP (1-36) fragment having similar activity as the full-length protein. PTHrP may have antitumorigenic properties [18, 19 ] and PTHrP (107-139), also known as osteostatin, may inhibit osteoclastic bone resorption [20, 21] .
Despite differences between PTH and PTHrP protein structure, both bind to a common PTH/PTHrP receptor (PTH1R) [22, 23] . Three mechanisms of PTH1R activation by PTH that increase serum calcium and alter phosphate homeostasis are well described: PTH activates osteoclastic bone resorption and release of skeletal calcium and phosphate through increased osteoblast receptor activator of nuclear factor kB ligand (RANKL) expression leading to activation of the receptor activator of nuclear factor kB (RANK) located on osteoclast precursors [24] . PTH increases calcium reabsorption in the loop of Henle ascending limb and distal convoluted tubule [25] and inhibits phosphate reabsorption in the proximal convoluted tubule [26] . PTH increases renal 1a-hydroxylase with production of 1,25-dihydroxyvitamin D [1,25-(OH) 2 D], the active form of vitamin D, in the proximal convoluted tubule resulting in targeted intestinal absorption of calcium and phosphate [27] .
PTHrP has equivalent actions as PTH in regulating bone resorption and renal calcium/phosphorus. However, unlike PTH, PTHrP does not increase 1a-hydroxylase activity and 1,25-(OH) 2 D production. This is illustrated in patients with primary hyperparathyroidism who generally have an elevated circulating 1,25-(OH) 2 D, which is reflective of heightened PTH activity. Such an increase is not seen in patients with PTHrP-dependent HHM, even though stores of the vitamin D precursor may be normal [28] . Differences between PTH and PTHrP ligandreceptor binding kinetics and activation of PTH1R downstream signaling pathways are the likely mechanisms responsible for this difference [23, 29] . The discordant effects between PTH and PTHrP on 1,25-(OH) 2 D production were confirmed in human controlled trials studying PTH (1-34) versus PTHrP (1-36) infusion [30] .
Normally, PTHrP circulates at a concentration of less than 2.0 pmol/l. Approximately 80% of the hypercalcemic patients with solid tumors have plasma PTHrP concentration above this value [31, 32] . Hypercalcemia ensues only when PTHrP reaches a threshold concentration that replaces and surpasses the analogous actions of PTH. Hypercalcemia attributed to elevated concentrations of humoral PTHrP has been estimated to occur in 33-84% of breast cancers [33] [34] [35] [36] [37] [38] , 46-76% of lung cancers [35, 36, 38] , 21-63% of non-Hodgkin's lymphomas (NHLs) [38] [39] [40] and 92% of adult T-cell leukemia/ lymphomas due to the human T-lymphotropic virus type 1 (HTLV-1) infection [39] . Infrequently, PTHrPmediated hypercalcemia occurs in head and neck tumors [41, 42] , renal cell carcinoma [43, 44] , bladder cancer [45] , pancreatic carcinoma [46] , hepatocellular carcinoma [47] , carcinoid tumors [48] and melanoma [49] .
Parathyroid hormone and humoral hypercalcemia of malignancy
PTHrP is responsible for the vast majority of cases HHM. However, rare cases have been reported of ectopic PTH secretion by tumors, which is often clinically indistinguishable from primary hyperparathyroidism. Suspicion of malignancy-associated ectopic PTH should arise in a patient with a known malignancy that has an elevated calcium and PTH, and when a standard technetium ( 99m Tc) sestamibi scan does not identify a parathyroid adenoma in the neck. Ectopic PTH production has been 340 Parathyroids, bone and mineral metabolism
Key points
Hypercalcemia of malignancy is associated with a poor prognosis. PTHrP is a common mediator of humoral hypercalcemia of malignancy. Local production of PTHrP and other factors mediate local bone osteolysis and hypercalcemia during bone metastasis. Saline hydration and bisphosphonates are the key therapies for hypercalcemia of malignancy. documented in a small cell carcinoma of the lung [50] , a squamous cell carcinoma of the lung [51] , an ovarian cancer [52] , a widely metastatic primitive neuroectodermal tumor [53] , a papillary adenocarcinoma of the thyroid [54] , a thymoma [55] , a rhabdomyosarcoma [56] and a pancreatic cancer [57] . [61] . In one report, 4.1% of the patients with newly diagnosed NHL were hypercalcemic and the likelihood of hypercalcemia increased with the higher grade of disease [61, 62] . The incidence of hypercalcemia with Hodgkin's lymphoma is similar to NHL with 5.4% of patients diagnosed with this complication [62] . Hypercalcemia from production of 1,25-(OH) 2 D in acute lymphoblastic leukemia and dysgerminomas are a rare complication of these malignancies [63, 64] .
Bone metastasis and skeletal osteolysis
Extensive bone metastasis and local osteolysis accounts for approximately 20% of cases of malignancy-associated hypercalcemia [32] . During massive osteolysis, the amount of calcium released from bone is greater than the renal calcium excretion capacity resulting in a net increase in serum calcium. Hypercalcemia-related nausea, anorexia, nephrogenic diabetes insipidus and volume depletion further impair renal function and exacerbate hypercalcemia.
The most common malignancy associated with this mechanism of hypercalcemia is breast cancer metastasis to bone, a complication that occurs in 70% of patients with advanced disease. The formation of bone metastasis begins with a series of sequential steps starting with cancer cell escape from the primary tumor site, embolization in the circulation followed by cancer cell adherence to bone vascular endothelium and extravasation into the bone microenvironment [65] . With the arrival of cancer cells to bone, a unique synergetic interaction between cancer and bone was first recognized by Stephen Paget [66] in 1889 and formed the basis for the 'seed and soil' hypothesis.
Humoral PTHrP is responsible for most cases of hypercalcemia in lung cancer, but 30-40% of the patients with advanced disease develop bone metastasis and hypercalcemia with localized osteolysis [67] . Multiple myeloma is far less common than breast or lung cancer, but osteolytic bone lesions are a nearly universal feature in advanced cases. Although not typically characterized as a metastatic malignancy, multiple myeloma shares many of the molecular mechanisms of pathologic bone resorption with breast cancer bone metastasis [65] . Other malignancies rarely causing hypercalcemia and osteolytic bone disease include melanoma [68] , acute lymphoblastic leukemia [69] [70] [71] and NHL [72, 73] .
PTHrP secretion into the metastatic bone microenvironment is the principal mechanism of pathogenic osteoclast activation and osteolysis from breast and lung cancer bone metastasis [74] [75] [76] [77] . PTHrP also plays a significant role in the process of metastasis to bone, as evidenced by clinical studies indicating that PTHrP expression by primary breast cancer is more commonly associated with the development of bone metastasis and hypercalcemia [78] . In the case of breast and lung cancer, HHM and skeletal osteolysis share PTHrP as the principal factor leading to hypercalcemia; in one situation, it is a local mediator, whereas in another, it is a humoral mediator. Multiple myeloma secretes a complement of osteoclast activating factors that include macrophage inflammatory protein-1a [79] , receptor activator of nuclear factor kB ligand (RANKL) [80] , interleukin-3 and interleukin-6 [81, 82] .
Differential diagnosis
Hypercalcemia, especially in the hospital setting and when the serum calcium is above 13 mg/dl, is likely due to malignancy. In the outpatient setting, primary hyperparathyroidism is a more likely cause of hypercalcemia. Therefore, hypercalcemia in a patient with a known malignancy may not necessarily indicate an advanced disease stage or even be linked to the malignancy itself [83] . In one study, seven out of 47 patients with hypercalcemia and a malignancy had coexisting primary hyperparathyroidism [84] . Differentiating between the two has prognostic value because the likelihood of survival past 100 days is likely with primary hyperparathyroidism, whereas an elevated PTHrP was associated with a high mortality within 100 days [84] .
Other conditions associated with hypercalcemia including excessive calcium intake, vitamin D toxicity and thiazide diuretics may also coexist in malignancy. It is therefore critical to fully evaluate the cause of hypercalcemia in all the patients with malignancy, even in those with advanced disease.
Assessing circulating intact PTH concentration is the initial step in determining the cause of hypercalcemia in all patients. During hypercalcemia of malignancy and in the absence of parathyroid disease, hypercalcemia will overactivate the calcium-sensing receptor of the parathyroid glands resulting in suppressed PTH production. In patients without a known malignancy, PTHrP testing is generally not necessary in the initial diagnostic workup of hypercalcemia. In patients with a malignancy and hypercalcemia, both PTH and PTHrP should be measured.
Treatment
The principal goals are two-fold: restore and promote renal calciuresis and inhibit pathologic osteoclastic bone resorption.
Hydration
Volume resuscitation is a critical early treatment to restore renal perfusion and calciuresis [85] . The rate of hydration depends on the severity of hypercalcemia, the age of the patient and comorbidities such as congestive heart failure, which may limit the rate of saline infusion. A 1-liter normal saline bolus followed by 200-300 ml/h is a reasonable approach. Once euvolemia is established, either oral or maintenance intravenous fluids is continued to maintain a reasonable urine output. The addition of furosemide to promote calciuresis is generally not recommended given the paucity of clinical evidence supporting its use in this setting [86] .
Calcitonin
Calcitonin is a useful adjunctive initial therapy that inhibits osteoclastic bone resorption and renal calcium reabsorption. A disadvantage of calcitonin is the development of tachyphylaxis within 48 h of initiation. The effectiveness of this medication can be extended with the combination of glucocorticoids [87] . Calcitonin is administered either intramuscularly or subcutaneously at a dose of 4 U/ kg every 12 h up to 8 U/kg every 6 h if the initial dose is not satisfactory. Intranasal administration of calcitonin has shown not to be effective [88] . Few studies have examined the efficacy of calcitonin alone in the acute management of hypercalcemia of malignancy [87, 89] .
Bisphosphonates
Pamidronate and zoledronic acid are the two bisphosphonates approved by the US Food and Drug Administration for treatment of hypercalcemia of malignancy. These nitrogen-containing bisphosphonates have a high affinity for hydroxyapatite and are rapidly deposited within bone after administration. Bisphosphonate released during bone resorption becomes internalized within the osteoclast, blocking prenylation of small GTP-binding proteins important for structural integrity of the osteoclast resulting in apoptosis [90 ] .
Clinical trials have demonstrated efficacy of both 60 and 90 mg doses of pamidronate administered intravenously over 4 h [91, 92] . The higher 90 mg dose can be used in patients with more severe hypercalcemia. With the 90 mg infusion of pamidronate, the mean time to normocalcemia was approximately 4 days, whereas the mean duration of normocalcemia was 28 days in one study [93] . An effective method for achieving a rapid and sustained reduction in serum calcium concentration is to use pamidronate in combination with calcitonin. The combination of the durable action of a bisphosphonate with rapid-acting calcitonin lowers serum calcium levels more rapidly and effectively than either alone [94] .
Zoledronic acid, a more potent bisphosphonate, is administered at a dose of 4 mg intravenously over 15 min. Compared with pamidronate, zoledronic acid was superior in respect to response rates, time to calcium normalization and response duration [95] . Therefore, many clinicians consider zoledronic acid the bisphosphonate of choice. The bisphosphonate ibandronate, currently approved in the USA for osteoporosis treatment, has similar efficacy as pamidronate but is not yet approved by the FDA for this indication [96] . Etidronate and clodronate have been studied in hypercalcemia of malignancy, but the availability of more potent bisphosphonates has supplanted the use of these low-potency first-generation bisphosphonates. Disadvantages of bisphosphonates are renal toxicity that can be minimized with a dose adjustment and risk of osteonecrosis of the jaw especially in patients who receive multiple doses and those with poor dentition [97 ] .
Glucocorticoids
Glucocorticoids are the preferred therapy for patients with 1,25-(OH) 2 D-mediated hypercalcemia and operate by reducing extrarenal vitamin D 1a-hydroxylase activity. Glucocorticoids also inhibit osteoclastic bone resorption by decreasing tumor production of locally active cytokines and maybe used in conjunction with other standard therapies in patients with other forms of hypercalcemia of malignancy [87, 98] . Prednisone at dose of 40-60 mg administered daily is typically effective. If no appreciable response is observed within 10 days, then glucocorticoid therapy should be discontinued.
Other therapies
Plicamycin and gallium nitrate are two antineoplastic agents that have calcium-lowering abilities. However, these medications are no longer recommended for treating hypercalcemia of malignancy due to poor side-effect profiles and inconvenient dosing schedules. Hemodialysis using a calcium-free dialysate effectively lowers calcium in case reports [99, 100] . This mode of therapy should be reserved only for the most severe cases of hypercalcemia when rapid normalization of calcium is required. Denosumab is a RANKL-targeted monoclonal antibody currently approved for treating osteoporosis and preventing skeletal-related events in bone metastasis [101, 102 ] . The efficacy of denosumab for treating hypercalcemia of malignancy is currently being evaluated in a phase II clinical trial.
Conclusion
Hypercalcemia is a common complication of malignancy caused by a heterogeneous group of tumor-derived factors that disrupt normal calcium homeostasis. PTHrP, either acting as endocrine factor or locally in cancer metastasis to bone, is a central mediator of this paraneoplastic complication in breast and lung cancer. A complement of other factors is the foundation for hypercalcemia associated with multiple myeloma. Rarely, tumorproduced PTH and 1,25-(OH) 2 D are implicated. The standard of care for hypercalcemia of malignancy in most cases is bisphosphonate treatment combined with saline hydration. Alternative therapies with potential benefit include inhibitors of RANKL and neutralizing antibodies to PTHrP. Clinical trials, in progress, should determine whether these modalities would be as effective or complementary to bisphosphonate treatment.
